Ipamorelin vs MK-677 (Ibutamoren): Switching Between Them
HealthRX.com
No tested way to switch between ipamorelin and MK-677
At a glance
- Approval status / Neither is FDA-approved for any use [5][3]
- Molecule type / Ipamorelin: synthetic pentapeptide; MK-677: oral non-peptide small molecule, not a SARM [6][3]
- Route in human studies / Ipamorelin: intravenous only; MK-677: oral [5][3]
- Duration / Ipamorelin half-life about 2 hours; MK-677 reported active about 24 hours after a dose [2][3]
- FDA compounding status / Ipamorelin: category 2 for outsourcing facilities; MK-677: category 2 on both lists [4][7]
- Sport / Both named in WADA S2.2.4, prohibited at all times [8][9]
- Switch-specific studies / We found no study that tested a switch
- Documented signals / MK-677: congestive heart failure signal in a hip-fracture trial; ipamorelin: low potassium, high blood sugar, insomnia in an ileus trial [10][11]
Is there a tested way to switch from one to the other?
No published study has moved people from ipamorelin to MK-677 or the reverse, so no washout interval for switching between them has been established. A separate MK-677 crossover study used a 14- to 21-day washout between its own treatment periods, but it did not involve ipamorelin [1]. Neither drug has an approved dose, so there is no labeled dose to convert between [5][3].
Ipamorelin was developed as an investigational drug for postoperative ileus, and that development was reportedly discontinued after disappointing phase 2 results [5]. MK-677 was first synthesized by Merck in 1995 and its development was discontinued in 1999; it is also under study as LUM-201 for pediatric growth hormone deficiency [3][12].
Questions worth asking
What the pharmacology says about timing
Ipamorelin. In healthy male volunteers given 15-minute intravenous infusions of 4.21 to 140.45 nmol/kg, concentrations were dose-proportional, with a terminal half-life of about 2 hours, clearance of 0.078 L/h/kg and steady-state volume of distribution of 0.22 L/kg. Growth hormone rose in a single sharp peak about 0.67 hours after the infusion and fell to negligible levels at every dose [2]. FDA found no human pharmacokinetic, safety or efficacy data for subcutaneous ipamorelin [5].
MK-677. FDA's review reports only that MK-677 has high oral bioavailability and a long duration of action, with a single dose active for about 24 hours, and found no further human pharmacokinetic data [3]. In animal studies the growth hormone response can be lost during continuous oral treatment [3].
A terminal half-life and a reported duration of activity are different measures, and no study has used either to define a switching interval.
Are the two interchangeable?
No. Ipamorelin is a synthetic pentapeptide containing unnatural amino acids that stimulates growth hormone release at the ghrelin/GH-secretagogue receptor rather than the GHRH receptor [6][5]. Most of what is claimed about its selectivity comes from animal work: in rats and pigs it released growth hormone with potency similar to GHRP-6, and in swine it did not change FSH, LH, prolactin or TSH [6].
MK-677 is not a peptide. It is an oral, non-peptide small molecule that acts on the ghrelin receptor, and it is not a SARM, although it is often sold alongside them [3]. Both compounds stimulate growth hormone release, but no trial compares their IGF-1 effects. MK-677 has raised IGF-1 in clinical trials, while FDA says ipamorelin may carry risks involving the GH/IGF-1 axis. Neither is approved [5][3].
What the clinical trials measured
Ipamorelin. One phase 2 trial has been published: 117 adults were enrolled after bowel resection and 114 were analyzed, receiving ipamorelin 0.03 mg/kg intravenously twice daily from postoperative day 1 to 7 or discharge, versus placebo. Median time to first tolerated solid meal was 25.3 hours versus 32.6 hours (p=0.15, not significant). Secondary GI-recovery endpoints did not differ, and only a subgroup of open-surgery patients showed shorter bowel recovery. Any treatment-emergent adverse event occurred in 87.5% on ipamorelin versus 94.8% on placebo [11].
MK-677. These trials randomized participants to MK-677 or placebo:
- In a 12-month comparison within a 2-year crossover trial, 65 healthy adults aged 60 to 81 received MK-677 25 mg daily or placebo. Fat-free mass rose 1.1 kg with MK-677 versus a 0.5 kg fall on placebo, body weight rose 2.7 kg versus 0.8 kg, fasting glucose rose about 5 mg/dL with lower insulin sensitivity, and strength and function did not improve [13].
- In a randomized trial of 123 hip-fracture patients, 62 received MK-677 25 mg daily for 24 weeks and 61 received placebo; the trial was stopped early for a safety signal of congestive heart failure. IGF-1 rose 51.4 ng/mL more than placebo, gait speed improved, and most other functional measures did not [10][3].
- In another randomized trial, 161 hip-fracture patients were assigned to MK-0677 25 mg daily or placebo for 6 months. IGF-1 rose 84% versus 17% on placebo, with no significant functional benefit [14].
- In a randomized trial of 563 patients with mild to moderate Alzheimer's disease, participants received MK-677 25 mg daily or placebo for 12 months. IGF-1 rose 72.9% with MK-677, but progression measures did not differ [15].
- In a randomized trial of 24 obese men, 12 received MK-677 25 mg daily and 12 received placebo for 8 weeks. IGF-1 rose about 40% with MK-677 and fat-free mass increased, but total and visceral fat did not change and an oral glucose tolerance test showed impaired glucose handling at 2 and 8 weeks [16].
What the trials recorded as side effects
MK-677. In the 123-patient hip-fracture trial, 4 patients (6.5%) on MK-677 versus 1 (1.7%) on placebo developed congestive heart failure per FDA's summary; blood pressure was higher, serious adverse events occurred in 24% versus 13%, and glucose and HbA1c rose more [10][3]. In the 161-patient hip-fracture trial, serious adverse events occurred in 24% versus 18%, thrombosis in 4 versus 0, glucose rose 8.0 versus a 1.6 mg/dL fall, HbA1c rose 0.7% versus 0.3%, and edema or fluid overload affected 16 versus 10 patients [14][3]. In the Alzheimer's trial, drug-related adverse events were 35.5% versus 23.9%, blood glucose increases 15.4% versus 4.6%, and HbA1c increases 11.1% versus 1.4% [15][3]. The 12-month study in healthy older adults reported increased appetite, transient mild leg edema and muscle pain as the most frequent side effects, and cortisol rose [13][3].
FDA's overall conclusion from these trials lists serious concerns including hyperglycemia, liver enzyme elevations, edema and fluid overload, and congestive heart failure in elderly patients recovering from hip fracture; other reported events include musculoskeletal pain, increased appetite and raised prolactin. Serious events across studies included congestive heart failure, thrombosis, cancer and myocardial infarction. FDA says that by raising GH and IGF-1, MK-677 may carry the risks listed on approved growth hormone labels, including increased risk of neoplasm, glucose intolerance and diabetes, intracranial hypertension, fluid retention, hypothyroidism and pancreatitis [3].
Ipamorelin. In the ileus trial, low potassium occurred in 12.5% on ipamorelin versus 3.4% on placebo, insomnia in 10.7% versus 5.2%, high blood sugar at discharge in 14.3% versus 8.6%, and serious adverse events in 17.9% versus 15.5%. Two ipamorelin-treated patients died of surgical complications; FDA said it is unclear whether the deaths were related to ipamorelin, but they raise safety concerns [5][11].
FDA's stated compounding concerns are possible immunogenicity for certain routes because of aggregation and impurities, unnatural amino acids that complicate characterization, and a published study that identified serious adverse events including death when ipamorelin was given intravenously to improve gastric motility [4]. FDA also says that stimulating the GH and IGF-1 axis may carry the risks listed on approved growth hormone labels, and possibly QT prolongation as with the approved GH stimulator macimorelin [5].
Regulatory status of each
Ipamorelin is not an FDA-approved drug, is not a component of any FDA-approved drug and has no US Pharmacopeia monograph [5]. FDA lists ipamorelin acetate in category 2 for outsourcing facilities, added September 29, 2023 and still listed on the page dated April 22, 2026 [4][17]. For state-licensed pharmacies and physicians it appears in the nominated-but-withdrawn table and in none of the three categories on FDA's list updated May 14, 2026, so FDA's category 1 policy does not apply to it [4][7]. On October 29, 2024 FDA's Pharmacy Compounding Advisory Committee voted 0 yes, 12 no, 1 abstention on both ipamorelin free base and ipamorelin acetate, citing a lack of information supporting safety and efficacy [18]. It is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [19].
Ibutamoren mesylate is also in category 2, added December 29, 2022 for outsourcing facilities and September 29, 2023 for state-licensed pharmacies and physicians, and still listed in 2026 [4][7][17]. FDA's stated reason is that it poses significant safety risks due to the potential for congestive heart failure in certain patients, citing the hip-fracture trial terminated early for that signal [4][10]. The advisory committee voted 1 yes, 13 no against adding it to the pharmacy bulks list, citing fluid retention, congestive heart failure and hyperglycemia [18]. It is not among the six peptides in the HHS draft policy [20][19].
In a December 12, 2025 warning letter, FDA stated that ibutamoren is excluded from the dietary supplement definition and that products marketed with drug claims for it are unapproved new drugs [21]. On September 23, 2025 FDA warned that a children's growth product contained undeclared ibutamoren, and listed risks including increased appetite, water retention, fatigue, muscle pain, changes in glucose metabolism and insulin sensitivity, and a possible increased potential for congestive heart failure in certain individuals [22].
WADA names both ipamorelin and ibutamoren (MK-677) in section S2.2.4 as growth hormone secretagogues and mimetics. Both are prohibited at all times, in and out of competition, on the 2026 and 2027 Prohibited Lists [8][9].
Bottom line
The human data for the two compounds were collected differently. Ipamorelin's come from intravenous dosing, with a terminal half-life of about 2 hours and a single growth hormone peak [2]. For MK-677, FDA's review reports that a single oral dose is active for about 24 hours, with no further human pharmacokinetic data [3]. Neither finding establishes a switching interval. What unites them is regulatory status: neither is approved, both are in FDA's category 2 safety-risk list for compounding (ipamorelin for outsourcing facilities, MK-677 on both lists), and both are prohibited in sport [5][3][4][8].
Frequently asked questions
Can you switch from ipamorelin to MK-677?
Can ipamorelin and MK-677 be taken together?
Are ipamorelin or MK-677 FDA-approved?
Is MK-677 a peptide or a SARM?
Which one raises IGF-1 more?
Are ipamorelin and MK-677 banned in sport?
References
Show all 22 referencesHide references
- Murphy MG, Plunkett LM, Gertz BJ, He W, Wittreich J, Polvino WM, et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J Clin Endocrinol Metab. 1998;83(2):320-5.
- Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-6.
- U.S. Food and Drug Administration.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- World Anti-Doping Agency.
- Adunsky A, Chandler J, Heyden N, Lutkiewicz J, Scott BB, Berd Y, et al. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr. 2011;53(2):183-9.
- Beck DE, Sweeney WB, McCarter MD, Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-34.
- Bright GM, Do MT, McKew JC, Blum WF, Thorner MO. Development of a Predictive Enrichment Marker for the Oral GH Secretagogue LUM-201 in Pediatric Growth Hormone Deficiency. J Endocr Soc. 2021;5(6):bvab030.
- Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE, Clasey JL, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-11.
- Bach MA, Rockwood K, Zetterberg C, Thamsborg G, Hébert R, Devogelaer JP, et al. The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture. J Am Geriatr Soc. 2004;52(4):516-23.
- Sevigny JJ, Ryan JM, van Dyck CH, Peng Y, Lines CR, Nessly ML, et al. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology. 2008;71(21):1702-8.
- Svensson J, Lönn L, Jansson JO, Murphy G, Wyss D, Krupa D, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab. 1998;83(2):362-9.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- Official web page.
- U.S. Food and Drug Administration.
- Agebox iKids Growth Day Formula may be harmful due to hidden ingredient | FDA.